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Abstract
Introduction: Cell-free plasma mitochondrial DNA (mt-DNA) and nuclear DNA (n-DNA) are biomarkers with
prognostic utility in conditions associated with a high rate of cell death. This exploratory study aimed to determine
the plasma levels of both nucleic acids in patients with massive and submassive pulmonary embolism (PE) and to
compare them with other biomarkers, such as heart-type fatty acid-binding protein (H-FABP) and troponin I (Tn-I)
Methods: This was a prospective observational study of 37 consecutive patients with massive PE, 37 patients with
submassive PE, and 37 healthy subjects. Quantifications of plasma mt-DNA and n-DNA with real-time quantitative
polymerase chain reaction (PCR), and plasma H-FABP and Tn-I by commercial assays, were done on blood samples
drawn within 4 hours after presentation at the emergency department.
Results: Plasma mt-DNA and n-DNA concentrations were much higher in patients with massive PE (median, 2,970
GE/ml; interquartile range (IQR), 1,050 to 5,485; and 3,325 GE/ml, IQR: 1,080 to 5,790, respectively) than in patients
with submassive PE (870 GE/ml and 1,245 GE/ml, respectively; P < 0.01) or controls (185 GE/ml and 520 GE/ml,
respectively). Eighteen patients with massive PE died of a PE-related cause by day 15 of observation. Plasma mt-
DNA and n-DNA values were 2.3-fold and 1.9-fold higher in the subgroup of nonsurviving patients than in
survivors. H-FABP and Tn-I values were also higher in patients with massive PE who died (7.3 ng/ml and 0.023 ng/ml,
respectively) than in those who survived (6.4 ng/ml, and 0.016 ng/ml, respectively). By receiver operating curve (ROC)
analysis, the best cutoff values for predicting 15-day mortality were 3,380 GE/ml for mt-DNA, 6.8 ng/ml for H-FABP,
3,625 GE/ml for n-DNA, and 0.020 ng/ml for Tn-I, based on the calculated areas under the curve (AUCs) of 0.89
(95% confidence interval (CI), 0.78 to 0.99), 0.76 (95% CI, 0.69 to 093), 0.73 (95% CI, 0.58 to 0.91), and 0.59 (95% CI,
0.41 to 0.79), respectively. By stepwise logistic regression, a plasma mt-DNA concentration greater than 3,380 GE/ml
(adjusted odds ratio (OR), 8.22; 95% CI, 1.72 to 39.18; P < 0.001) and a plasma value of H-FBAP >6.8 ng/ml (OR, 5.36;
95% CI, 1.06 to 27.08; P < 0.01) were the only independent predictors of mortality.
Conclusions: mt-DNA and H-FBAP might be promising markers for predicting 15-day mortality in massive PE, with
mt-DNA having better prognostic accuracy.
Keywords: plasma mitochondrial DNA, plasma nuclear DNA, cell-free plasma DNA, heart-type fatty acid-binding
protein, hospital mortality, massive pulmonary embolism, prognosis
* Correspondence: farnalich.hulp@salud.madrid.org
1Department of Internal Medicine and Emergency Medicine Service, Hospital
Universitario La Paz. IdiPAZ. Paseo de la Castellana 261.28046 Madrid, Spain
Full list of author information is available at the end of the article
Arnalich et al. Critical Care 2013, 17:R90
http://ccforum.com/content/17/3/R90
© 2013 Arnalich et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Introduction
Massive pulmonary embolism (PE) is an infrequent car-
diovascular emergency that carries a very high mortality
rate [1,2]. Assessment of right ventricular (RV) function
and measurement of cardiac biomarkers (troponins,
brain natriuretic peptide (BNP), or heart-type fatty acid-
binding protein (H-FABP)) released to serum from the
RV, accurately predict 30-day mortality in patients with
submassive PE [3-7]. Unfortunately, no data are yet
available to support the usefulness of cardiac biomarkers
in predicting mortality in patients with massive PE [4].
Cell-free plasma DNA comprises small DNA fragments
derived from nuclear or mitochondrial double-stranded
molecules that are found at very low concentrations
circulating in peripheral blood from healthy people.
Both nuclear DNA (n-DNA) and mitochondrial DNA
(mt-DNA) are released into the circulation from apoptotic
and necrotic cells, although the exact mechanism is
unclear [8,9]. Cell-free plasma n-DNA and mt-DNA are
biomarkers with prognostic utility in a range of conditions
associated with a high rate of cell death, including trauma
[10], stroke [11], myocardial infarction [12], burns [13],
sepsis, and critical conditions [14-16]. We and others
reported that high concentrations of plasma n-DNA can
predict treatment outcomes and mortality in conditions
associated with global ischemia-reperfusion injury, such as
acute mesenteric ischemia and cardiac arrest [17-19]. High
plasma concentrations of both mt-DNA and n-DNA have
been found in patients with acute ischemic stroke, bacterial
meningitis, and sepsis [20-22], and with similar prognostic
values. In contrast, recent data indicate that increased mt-
DNA concentration is a more powerful prognostic marker
than plasma n-DNA in patients with out-of-hospital car-
diac arrest [23].
Detection of plasma DNA with counterimmunoelec-
trophoresis was proposed as a screening test for the
diagnosis of PE [24]. One study conducted two decades
ago showed that increased plasma DNA concentrations
had a sensitivity of 82% and a specificity of 85% in
detecting patients with PE [25], but no subsequent study
evaluated the potential prognostic value in patients with
high-risk PE. Examining this question is relevant
because those patients have widespread tissue hypoxia
that decreases oxygen availability for mitochondria, leading
to a rapid depletion of ATP synthesis and cell death via the
intrinsic pathway of apoptosis [26]. We hypothesized that
the amount of plasma mt-DNA, released to the circulation
from apoptotic cells, could be a good new marker of cell
damage caused by acute RV myocardial ischemia in
patients with massive PE.
This exploratory study aimed to determine the plasma
levels of both nucleic acids in patients with massive and
submassive PE presenting at the emergency department
(ED) and to compare them with other biomarkers, such
as heart-type fatty acid-binding protein (H-FABP) and
troponin I (Tn-I).
Materials and methods
Patients and setting
We performed a prospective observational study of
74 consecutive patients admitted to the ED with acute
massive or submassive PE, confirmed with computed
tomographic pulmonary angiography (CTPA), who were
classified into two groups: 37 patients with massive PE
and 37 patients with submassive PE, based on their sys-
tolic blood pressure on admission and the presence of
echocardiographic findings of right ventricular (RV) dys-
function. The study was conducted from January 2005
through May 2007 at La Paz University Hospital in
Madrid, Spain, an academic tertiary care hospital with
annual ED visits of around 120,000. Massive PE was
diagnosed in patients who met the following criteria:
(a) systolic blood pressure <90 mm Hg or a pressure
decrease of ≥40 mm Hg for >15 minutes at arriving in
the ED, requiring catecholamine administration to main-
tain adequate organ perfusion, if not due to new-onset
arrhythmia, hypovolemia, sepsis, acute coronary syndrome,
or acute left ventricular failure; (b) partial oxygen arterial
pressure ≤80 mm Hg while receiving supplemental oxygen
of 2 L/min, in the absence of pulmonary infiltrates on
chest radiograph film.
Submassive PE was diagnosed in patients who were nor-
motensive on admission and had echocardiographic signs
of RV dysfunction (see Additional file 1, methods). Exclu-
sion criteria were (a) end-stage heart or renal failure, (b)
clinical conditions that might be associated with increased
plasma DNA concentrations (metastatic cancer, multiple
trauma, stroke, severe sepsis or septic shock, acute myo-
cardial infarction, cardiac arrest). Sample size of the mas-
sive-PE group was estimated based on our previous
studies in patients with out-of-hospital cardiac arrest,
showing that plasma DNA concentrations were at least
1.5-fold higher in patients who died than in survivors
[18,23]. Assuming a mortality rate between 30% and 50%
in patients with massive PE, and that the magnitude of dif-
ferences in plasma nucleic acids between survivors and
nonsurvivors would be similar in massive PE, we estimated
that a sample size of 37 patients would be sufficient to
keep a type I (a) error of 0.05 and a type II (b) error of
0.20. The submassive-PE group consisted of the same
number of patients, matched in age and gender to the
massive-PE group. Each patient´s baseline characteristic
determined their risk classification, according to the pre-
dictive pulmonary severity index (PESI) model [27].
Thirty-seven healthy community subjects or relatives of
patients taking no medications, with a normal physical
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and analytic check-up, were recruited as the control group.
The study protocol was approved by the local research
ethics committee. All study and controls subjects or their
legal designees signed a written informed consent.
The end point of the study was 15-day PE-related
death. Cause of death was judged to be definitive fatal
PE, if it was confirmed by autopsy. Possible fatal PE was
considered in a patient who died suddenly or unexpect-
edly of severe PE in the absence of any alternative
cause. All patients received standard anticoagulation
therapy with intravenous unfractionated heparin or sub-
cutaneous low-molecular-weight heparin. Thrombolytic
therapy was strongly considered in patients with massive
PE. However, mainly because of high-risk bleeding (six
cases) or of the patient legal designee´s refusal to allow
thrombolysis (nine cases), only 20 patients were actually
given thrombolysis (2-hour infusion of 100 mg recombi-
nant tissue plasminogen activator).
Blood sampling, processing of plasma, and DNA
extraction
A 10-ml blood sample was taken within approximately
4 hours (range, 1 to 7 hours) from admission to the ED,
either before heparin administration or less than 2 hours
after heparin administration, during the diagnostic
workup. After confirmation of the diagnosis, patients or
their relatives were asked to authorize the use of throm-
bolytic therapy and to sign the informed consent form
for enrollment into the study. Therefore, in all the cases,
blood was obtained before thrombolysis. We prepared
and measured plasma DNA by the same methods we
used previously [17,18,23]. Plasma and cells were sepa-
rated by centrifugation at 1,800 g (+4ºC) for 10 minutes,
and plasma samples were stored at -80ºC. Afterward,
plasma was carefully removed from tubes without shak-
ing the buffy coat, transferred to plain polypropylene
tubes, and centrifuged at 16,000 g (+4ºC) for 10 minutes.
The supernatants were collected into fresh polypropylene
tubes and stored at -80ºC until further processing. Cell-
free DNA was extracted from 200-μl plasma samples
by using the QIAamp DNA Blood Mini Kit (Qiagen,
Hidden, Germany), according to the manufacturer’s
recommendations.
Real-time quantitative PCR
Cell-free plasma DNA copy numbers were measured
with real-time quantitative PCR assay (Roche Lightcy-
cler; Roche, Lewes, UK) by using specific primers to
amplify the b-globin and MT-ND2 genes [28,29].
Although the first gene is present in all nucleated cells
of the body, the second is unique to mitochondria. An
SYBR green-based assay for amplicon detection on the
ABI Prism 7900 device was used, as previously described
[28]. The following primers were designed for the
b-globin gene (GenBank accession number U01317):
354-forward (5′-GTGCACCTGACTCCTGAGGAGA-3′)
and 455-reverse (5′-CCTTGATACCAACCTGCCCAG-
3′), and for the MT-ND2 gene (GenBank accession num-
ber NC012920): 156-forward (5′-CACAGA AGCTGC-
CAT CAAGTA-3′) and 245-reverse (5′-CCGGAGAGTAT
ATTGTTGAAGAG-3′). Two amplicons of 101-bp (n-
DNA) and 90-bp (mt-DNA) were obtained, respectively,
in each of these PCR reactions. A 10-fold serial dilution of
human genomic DNA (Roche) was used to construct the
calibration curve, which was included in each PCR reac-
tion. The imprecision of this experimental approach was
previously reported [28,29], with an interassay CV of the
threshold cycle (Ct) values ranging from 0.5% to 1.1%.
Results are expressed as genome equivalents (GE)/ml
plasma (1 GE = 6.6 pg DNA), with a detection limit of
12.5 GE/ml.
Laboratory measurements
The plasma levels of different biomarkers were measured
as follows: (a) D-dimer by immunoturbidimetric assay
(INNOVANCE D-Dimer assay; Siemens Healthcare Diag-
nostics Products GmbH, Marburg, Germany); (b) Tn-I and
NT-proBNP with quantitative electrochemiluminescence
immunoassays (Dimension Vista System analyzer; Siemens
Healthcare Diagnostics, DE, USA); (c) H-FABP (dilution
1:5) by a solid-phase enzyme-linked immunoadsorbent
assay (HyCult Biotechnology, Uden, The Netherlands); (d)
markers involved in Fas-related apoptosis, human soluble
Fas (sFas), and soluble Fas ligand (sFasL) molecules, with
enzyme immunoassay (Quantikine; R&D Systems, Minnea-
polis, MN, USA) [see Additional file 1, methods]. All other
laboratory analyses were performed with standard techni-
ques. Renal insufficiency was defined as a glomerular filtra-
tion rate <60 ml/min/1.73 m2. The glomerular filtration
rate was calculated by using the abbreviated Modification
of Diet in Renal Disease formula [31].
Statistical analysis
Continuous variables are expressed as medians and inter-
quartile ranges (IQR, 25th to 75th percentiles) and com-
pared with the Mann-Whitney U test. Categoric variables
were given as absolute values and percentages and com-
pared with c2, by using the Fisher exact test when appro-
priate. We determined bivariate relations by using
nonparametric Spearman rank correlation. Receiver oper-
ating characteristic (ROC) curves were constructed to
determine the optimal cutoff values for maximal sensitivity
and specificity of different laboratory markers for predict-
ing the primary end point of 30-day mortality. Compari-
son of AUCs was performed as recommended by DeLong
et al. [32]. The results are presented as odds ratio (ORs)
with the corresponding 95% CIs. Kaplan-Meier analysis
was performed for cumulative survival, and log-rank
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values were used to assess statistical significance. All sig-
nificant variables were then tested in a multivariable logis-
tic regression analysis model by using forward variable
selection to identify factors that had independent predic-
tive value for 15-day mortality. Statistical significance was
set at P < 0.05 in all tests. All statistical analyses were per-
formed by using the SPSS for Windows 15.0 (SPSS Inc,
Chicago, IL, USA) and MedCalc 9.6.4.0 (MedCalc
Sofware).
Results
Eighteen (48.6%) patients with massive PE died by day 15
of observation, five of them during the first 48 hours. Ten
(58.8%) deaths occurred in the group of 17 patients who
did not receive thrombolysis, and eight (40.0%) deaths
among the 20 patients after thrombolysis. Three patients
died of PE confirmed at autopsy. Thirteen PE-related
deaths were caused by irreversible RV dysfunction in the
absence of any alternative diagnosis. In four other patients,
a major hemorrhage probably contributed to death. The
median duration of the ICU stay was 14 days (IQR, 5 to
20), and the median time until hospital discharge for survi-
vors was 32 days (IQR, 20 to 51). By contrast, in the sub-
massive-PE group, no deaths occurred, and only five
patients required ICU admission (median stay, 4 days). As
shown in Table 1, demographics and predisposing risk fac-
tors were not significantly different between patients with
massive and submassive PE or between patients with mas-
sive PE who died and those who survived. Patients´ symp-
toms and physical findings at presentation were similar in
survivors and nonsurvivors. The proportion of patients
with PESI (pulmonary embolism severity index) risk
classes V and the presence of obstructive shock were sig-
nificantly higher in nonsurvivors than in survivors. Table 2
displays baseline plasma concentrations of cardiac mar-
kers, soluble apoptosis-signaling molecules, mt-DNA, and
n-DNA in the three study subjects groups. Statistically sig-
nificant differences were observed among these variables
when all groups were compared (Kruskal-Wallis test; P <
0.01). Significantly higher values of all parameters were
observed in submassive and massive PE compared with
controls, as well as in the submassive-PE group compared
with massive-PE group (Mann-Whitney U test, corrected
by Bonferroni; P < 0.01). With regard to the massive-PE
group, the median cell-free plasma mt-DNA and n-DNA
concentrations at admission were higher in nonsurvivors
(4,220 GE/ml and 4,450 GE/ml, respectively) than in survi-
vors (1,830 GE/ml and 2,285 GE/ml, respectively; P <
0.01). Significantly higher plasma H-FABP and Tn-I levels,
but not significant differences in NT-proBNP concentra-
tions, were noted in patients who died compared with
survivors. A significant increase in sFas levels was found in
nonsurvivors. The baseline characteristics of massive-PE
patients who did and did not receive thrombolysis were
similar, except for the fact that thrombolysis patients had
significantly higher acidosis and hyperlactatemia. No sig-
nificant differences were found in plasma concentrations
of cardiac markers, apoptosis-signaling molecules, or
nucleic acids between both patient subgroups (see Addi-
tional file 2, Table S1). Total point scores of PESI were not
significantly associated with plasma concentrations of any
of these markers. Significant correlations were found
between plasma mt-DNA and n-DNA concentrations (r =
0.568; P < 0.01), and between each of them and H-FABP
values (r = 0.476 and r = 0.412, respectively; P < 0.01).
Plasma mt-DNA levels also correlated with lactate concen-
trations (r = 0.451; P < 0.01) and with sFas value (r =
0.379; P < 0.01). In contrast, no significant correlation was
noted between plasma n-DNA and lactate (r = 0.180; P =
0.115) or sFas values (r = 0.077; P = 0.624). Neither mt-
DNA nor n-DNA concentrations correlated significantly
with creatinine clearance.
ROC curves were calculated for the use of plasma of
mt-DNA and n-DNA and two specific cardiac markers,
H-FBAP and Tn-I, to predict 15-day mortality (Figures 1
and 2). The best cut-offs were 3,380 GE/ml for mt-DNA,
6.8 ng/ml for H-FABP, 3,625 GE/ml for n-DNA, and
0.020 ng/ml for Tn-I, based on the calculated AUCs of
0.89 (95% CI, 0.78 to 0.99), 0.76 (95% CI, 0.69 to 0.93),
0.73 (95% CI, 0.58 to 0.91), and 0.59 (95% CI, 0.41 to
0.79), respectively (Table 3). The AUC for mt-DNA was
similar to that for H-FBAP (P = 0.082) but significantly
higher than the AUC for n-DNA (P = 0.026), and higher
than the AUC for Tn-I (P = 0.015), in a comparison of all
four AUCs, according to DeLong´s method [32]. The dis-
criminant power of these cut-off values (sensitivity, speci-
ficity, positive and negative predictive value (PNV, NPV),
and likelihood ratio for positive (+LR) and negative
(-LR)) are shown in Table 3. Kaplan-Meier survival
curves using the best cutoff values of mt-DNA, H-FBAP,
and n-DNA are presented in Figure 3 (A through C).
We performed multiple logistic regression analysis to
identify factors having independent predictive value for
mortality. All parameters significantly associated with
hospital mortality by univariable analysis (the presence
of shock as the only categoric variable, and the serum
or plasma concentrations of analytic variables) were
included in a multivariable analysis. A plasma mt-DNA
concentration >3,380 GE/ml (adjusted OR, 8.22; 95% CI,
1.72 to 39.18; P < 0.001) and a plasma value of H-FBAP
>6.8 ng/ml (OR, 5.36; 95% CI, 1.06 to 27.08; P < 0.01)
were the only independent predictors of mortality.
Discussion
Earlier studies showed detectable plasma DNA in
patients with PE, but DNA was measured by using a
counter-immunoelectrophoresis technique that yielded
unsatisfactory results [24,25]. This is the first prospective
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Table 1 Descriptive characteristic of the study groups
Submassive Massive Pulmonary Embolism P value P value Healthy controls
P.Embolism
(n= 37)
Total
(n = 37)
Survivors
(n = 19)
Non-survivors
(n = 18)
A B (n = 37)
Demographics Age 67 (58-73) 68 (59-74) 66 (59-72) 70 (60-74) NS NS 65 (58-74)
Female 26 (70.2) 26 (70.2) 12 (63.1) 14 (77.7) NS NS 24 868.6)
Risk factors Obesity (BMI >30) 12 (32.4) 14 (37.8) 6 (31.5) 8 (44.4) NS NS
Immobilization (bed rest) 6 (16.2) 8 (21.6) 3 (15.8) 5 (27.7) Ns NS
Recent major surgery (< 30 d) 6 (16.2) 9 (24.3) 4 (21.1) 5 (27.7) NS NS
Chronic heart failure 10 (27.0) 12 (32.4) 5 (26.3) 7 (38.9) NS NS
COPD/emphysema 7 (18.9) 8 (21.6) 4 (21.1) 4 (22.2) NS NS
Cancer (inactive) 3 (8.1) 5 (13.5) 2 (10.5) 3 (16.6) NS NS
Previous DVT 6 (16.2) 7 (18.9) 4 (21.1) 3 (16.6) NS NS
Concurrent DVT 10 (27.0) 14 (37.8) 6 (31.5) 8 (44.4) NS NS
Unknown 14 (37.8) 13 (35.1) 7 (36.8) 6 (33.3) NS NS
Clinical data Acute onset of dyspnea 21 (56.7) 31 (83.8) 16 (84.2) 15 (83.3) <0.01 NS
Acute chest pain 9 (24.3) 13 (35.1) 6 (31.5) 7 (38.9) NS NS
Preceding syncope 3 (8.1) 15 (40.5) 7 (36.8) 8 (44.4) <0.01 NS
Systolic blood pressure, mm Hg 119 (113-128) 74 (68-83) 75 (69-82) 73 (67-83) <0.01 NS 125 (118-134)
Mean blood pressure, mm Hg 83 (77-91) 46 (38-54) 45 (39-54) 44 (38-52) <0.01 NS 86 (78-95)
PaO2 mm Hg 93 (90-97) 67 (64-72) 68 (64-73) 66 (63-72) <0.01 NS 95 (91-98)
PESI risk class III 11 (29.7) 0 (0.0) 0 (0.0) 0 (0.0) <0.01 NS
PESI risk class IV 20 (70.3) 16 (43.2) 9 (56.2) 7 (43.8) <0.01 NS
PESI risk class V 6 (16.2) 21 (56.8) 8 (38.1) 13 (61.9) <0.01 <0.05
Specific treatment Thrombolysis (within 24 h) 0 20 (54.5) 11 (57.9) 9 (50.0) — NS
Caval filter implantation 0 2 (4.4) 1 (5.3) 1 (5.5) — NS
Complications/outcome Obstructive shock (within 24 h) 2 (5.4) 18 (48.6) 6 (31.6) 12 (66.6) <0.01 <0.01
Mechanical ventilation 0 10 (27.0) 4 (21.1) 6 (33.3) <0.01 NS
Major bleeding 0 4 (10.8) 2 (10.5) 2 (11.1) — NS
Laboratory values pH 7.35 (7.32-7.38) 7.23 (7.19-7.27) 7.25 (7.18-7.31) 7.20 (7.16-7.27) <0.01 <0.05 7.38 (7.35-7.40)
Basal lactate (mmol/l) 2.2 (1.6-2.7) 5.7 (4.5-7.3) 4.9 (4.5-6.1) 6.4 (5.7-7.3) <0.01 <0.05 1.8 (1.3-2.1)
Estimated GFR (ml/min/1.73 m2) 69 (65-73) 65 (61-73) 67 (63-73) 63 (61-67) <0.01 NS 71 (66-75)
Data are median (IQR) or number (%); A: comparison of massive vs. submassive group.; B: comparison of survivors vs. non-survivors.
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Table 2 Comparison of factors associated with 15-day mortality.
Healthy controls
(n = 37)
Submassive PE
(n = 37)
Massive
PE
(n = 37)
Mann-Whitney U-test
(Massive vs Submassive PE)
Massive PE
Survivors
(n = 19)
Massive PE
Non-survivors
(n = 18)
Mann-Whitney U-test
(Non-survivors vs Survivors)
Troponin I (ng/ml) 0.003
(0.001-0.005)
0.009
(0.006-0.012)
0.019
(0.012-0.028)
-3.040
p <0.002
0.016
(0.012-0.023)
0.023
(0.014-0.28)
-2.042
p <0.04
D- dimer (μg/ml) 0.5
(0.1-0.8)
7.8
(4.1-10.4)
12.6
(8.2-15.8)
-2.309
p <0.021
11.9
(8.2-15.3)
13.7
(10.6-15.8)
-1.004
NS
NT-proBNP (pg/ml) 235
(130-350)
570
355-840
1720
(770-3185)
-2.750
p <0.006
1510
(770-2140)
1940
(950-3185)
-1.332
NS
H-FBAP (ng/ml) 1.4
(0.8-2.1)
3.1
(1.6-4.2)
6.8
(5.7-7.8)
-3.520
p <0.001
6.4
(5.7-7.4)
7.3
(6.1-7.8)
-2.839
p <0.05
Plasma n- DNA (GE/ml) 520
(230-760)
1245
(680-2315)
3325
(1080-5790)
-3.039
p <0.002
2285
(1280-4010)
4450
(1130-5780)
-2.750
p <0.016
Plasma mt- DNA (GE/ml) 185
(70-430)
870
(365-1690)
2970
(1050-5485)
-4.151
p <0.000
1830
(1050-3215)
4220
(2110-5510)
-3.769
p <0.001
Plasma sFas (pg/ml) 1070
(530-1650)
3355
(640-6720)
8940
(5330-13270)
-2.408
p <0.013
7680
(6330-9400)
10570
(9050-12870)
-2.355
p <0.019
Plasma sFasL (pg/ml) 460
(355-540)
510
(285-580)
790
(570-920)
-1.265
NS
755
(570-845)
810
(640-920)
-1.265
NS
Data are median (IQR);
COPD: chronic obstructive pulmonary disease; DVP: deep venous thrombosis; pro-BNP: pro-Brain Natriuretic Peptide; H-FBAP: heart-type fatty acid-binding protein; sFas: soluble Fas molecule; sFasL: soluble Fas ligand
molecule.
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observational study to evaluate cell-free plasma mt-DNA
and n-DNA concentrations by real-time specific PCR in
patients with massive and submassive PE presenting at
the ED and to compare them with two specific cardiac
markers, H-FABP and Tn-I. We found that plasma
concentrations of mt-DNA and n-DNA, H-FABP, and
Tn-I were significantly higher in patients with massive
PE than in patients with submassive PE. Significantly
higher values of these biochemical markers were
observed in nonsurviving patients with massive PE than
in those who survived. For the prediction of hospital
mortality, plasma mt-DNA showed a better discrimina-
tive power than that of the other biochemical markers.
Furthermore, by multivariable logistic regression analysis,
plasma mt-DNA and H-FABP values >3,380 GE/ml and
6.8 ng/ml, respectively, were independent predictors of
mortality. However, plasma n-DNA was not an indepen-
dent predictor and showed less prognostic accuracy.
This report adds new information to existing literature
for the study of cell-free plasma circulating nucleic acids
in critically ill patients [10-17]. Recently, we and others
found elevated plasma levels of cell-free n-DNA in car-
diac-arrest patients during the early postresuscitation
phase [18,19], a period when reperfusion after whole-
body ischemia may trigger a systemic inflammatory
response similar to that seen in severe sepsis, causing the
release of DNA from damaged cells. Similarly, after mas-
sive PE, patients have widespread ischemic tissue damage
derived from impaired lung function and abrupt systemic
arterial hypotension. When appropriate treatment is
started in these patients, the sudden return of oxygen at
the onset of reperfusion with restoration of mitochon-
drial respiration will increase mitochondrial ROS forma-
tion to a level that exceeds the antioxidant capacity of
the cells [33], causing mitochondria membrane rupture.
Thus, it is likely that plasma mt-DNA will be a good new
marker of the intensity of cell damage associated with
ischemia and reperfusion injury. mt-DNA has been
found to be a good early prognostic marker in out-of-
hospital cardiac-arrest patients [23]. The current study
demonstrates that plasma mt-DNA and n-DNA levels
increase shortly after submassive or massive PE, and this
elevation can be related to clinical severity and hospital
mortality. Elevated mt-DNA is a strong predictor of
15-day mortality in massive PE, and it has better prog-
nostic accuracy than n-DNA. Therefore, in contrast to
previous reports testing simultaneously mt-DNA and
n-DNA in different conditions [20-22], our data indicate
that measurement of both markers is not necessary to
increase the prognostic value.
Elevated plasma Tn-I and H-FBAP levels are associated
with RV dysfunction and have demonstrated significant
prognostic value for risk stratifying in patients with nor-
motensive PE [34,35]. However, their usefulness in the
setting of massive PE remains unknown. In the present
study, we found a significantly higher plasma concentra-
tion of H-FABP in nonsurviving than in surviving
patients, but, even so, this marker was not so good a pre-
dictor of mortality as was plasma mt-DNA. A plausible
 
Sensitivity 
1-Specificity 
 
a) mt-DNA (AUC 0.89) 
b) H-FABP (AUC 0.76) 
a) b) 
Figure 1 ROC curves for the use of plasma mt-DNA, and H-FBAP
concentrations to predict 15-day mortality. Plasma mt-DNA had
better predictive value (AUC, 0.89; 95% CI, 0.78 to 0.99) than did
plasma H-FBAP (AUC, 0.76; 95% CI, 0.69 to 0.93). The best cut-off
value of plasma mt-DNA at admission was 3,380 GE/ml (sensitivity,
94.4%; specificity, 68.4%). The best cut-off value of plasma H-FBAP
was 6.8 ng/ml (sensitivity, 88.9%; specificity, 85.7%).
1-Specificity 
Sensitivity 
 
a) n-DNA (AUC 0.73) 
b) Tn-I  (AUC 0.59) 
 
 
Figure 2 ROC curves for the use of plasma n-DNA and Tn-I, to
predict 15-day mortality. The best cut-offs were 3,625 GE/ml for
n-DNA, and 0.020 ng/ml for Tn-I, based on the calculated AUCs of 0.73
(95% CI, 0.60 to 0.91) and 0.599 (95% CI, 0.41 to 0.79), respectively.
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explanation is that mt-DNA as a nonspecific global mar-
ker of cell death might better reflect the degree of wide-
spread ischemic tissue damage that occurred in massive
PE.
Our study showed that the basal lactate concentrations
were significantly higher in hospital nonsurvivors than in
survivors. Hyperlactatemia in critically ill patients may be
attributed to anaerobic glycolysis resulting from inade-
quate tissue oxygenation, or it may be mediated by inflam-
mation [36]. Excessive lactate production in our patients
with acute PE is probably driven by two mechanisms,
ischemia-reperfusion injury and the systemic inflammatory
response, which both cause severe cell damage. The signif-
icant correlation between lactate concentrations and both
mt-DNA and n-DNA observed in this study could be a
direct consequence of the hypoxia-induced apoptosis and
systemic inflammation.
This study provides some evidence regarding the origin
of plasma nucleic acids from apoptotic cell death. Apopto-
sis is generated mainly by the Fas system. Fas (CD95) is a
transmembrane protein that transduces a cell-death signal
to the cytoplasm on its cross-linking with the Fas ligand
(FasL). Hypoxia-induced cell death is known to occur
mainly via the mitochondrial (intrinsic) pathway of apop-
tosis [37], which could explain the stronger relation we
found between sFas and mt-DNA. Our results are in line
with the findings of histologic analysis of RV muscle from
patients with fatal PE that shows accumulation of mono-
cytes/macrophages in the RV, but without histologic evi-
dence of cell necrosis [38]. Also, our findings are in
keeping with recent data showing a high plasma cell-free
nuclear DNA concentration and apoptotic DNA fragmen-
tation in patients with bacteremia [39]. Further investiga-
tion is needed on the association of circulating markers of
apoptosis, plasma mt-DNA concentration, and outcome in
critical illness, particularly in massive PE.
Some methodologic limitations have to be considered
in this study. First, the levels of the plasma nucleic acids
may be influenced by age and underlying diseases. How-
ever, because no differences in age, predisposing factors,
or comorbidities were found in survivors and nonsurvi-
vors, it is likely that differences in plasma mt-DNA and
n-DNA levels reflect the acute event of massive PE
rather than chronic illness.
Second, excessive accumulation of DNA in plasma
may be partly due to a decrease in clearance efficiency.
We found that serum urea or creatinine concentrations
were not independently associated with plasma mt-DNA
and n-DNA concentrations, and this is consistent with
data from experimental studies suggesting that renal
clearance is not the main mechanism of removal for
nucleic acids from the circulation [41-43]. However,
further investigations are required to understand the
dynamics of plasma DNA removal in patients with
impaired renal and hepatic function.
Third, some potential confounders, such as patient
management in the emergency department and intensive
care unit, are difficult to control.
Fourth, we studied plasma levels only in the emergency
department and did not measure levels serially, so we can-
not assess the variation of nucleic acid levels in the inten-
sive care unit or over time.
Fifth, our study design allows us to evaluate only asso-
ciations, and not causes. Opposing these limitations, the
Table 3 ROC curves comparing the discriminant power of mt-DNA, H-FBAP, n-DNA and Tn-I to predict 15-day
mortality in massive PE.
Test Cutoff AUC
(95% CI)
Sens.
(95% CI)
Spec
(95% CI)
PPV
(%)
NPV
(%)
+LR -LR P value
mt-DNA 3380 GE/ml 0.89
(0.78-0.99)
94.4
(82.0-95.6)
68.4
(64.1-87.5)
73.9 92.9 17.6 0.08 <0.001
H-FBAP 6.8 ng/ml 0.76
(0.69-0.93)
88.9
(78.3-93.1)
85.7
(76.8-91.8)
69.5 85.7 6.2 0.13 <0.001
n-DNA 3625 GE/ml 0.73
(0,58-0.91)
77.8
(64.1-85.5)
57.9
(48.2-71.4)
63.6 73.3 5.03 0.38 <0.05
Tn-I 0.020 µg/ml 0.59
(0.41-0.79)
66.7
(51.3-78.0)
47.4
(35.2-60.1)
54.5 60.0 0.75 0.70 NS
Survival 
rate   % 
Follow-time (days) 
mt-DNA < 3380 GE/ml  
 
mt-DNA ≥ 3380 GE/ml  
p  < 0.001 
A
Figure 3 Kaplan-Meier survival curve analysis according to the
plasma concentration of (A) mt-DNA level higher or lower than
3,380 GE/ml; log rank: c2, 13.71; P < 0.001. (B) H-FBAP level higher
or lower than 6.8 ng/ml; log rank: c2, 12.65; P < 0.001. (C) n-DNA level
higher or lower than 3,625 GE/ml; log rank: c2, 6.84; P < 0.009.
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strengths of this study lie, first, in the prospective design
that includes a clearly defined group of patients with
massive and submassive PE. Second, we made a com-
plete recording of predisposing risk factors, clinical and
laboratory covariates, and cardiac biomarkers of severity,
particularly H-FABP, against which plasma mitochon-
drial and nuclear DNA may be compared.
Third, it explores the potential association of apopto-
sis and soluble apoptotic signaling molecules with circu-
lating nucleic acids.
Conclusions
This study first demonstrates that plasma levels of mt-
DNA and n-DNA, and those of H-FABP and Tn-I, were
significantly higher in patients with massive PE compared
with those with submassive PE. Significantly higher values
of all of them were observed in nonsurviving patients with
massive PE than in those who survived. For the prediction
of hospital mortality, plasma mt-DNA and H-FBAP
showed better discriminative power than did n-DNA. The
significant association we found between plasma concen-
trations of both nucleic acids and the indirect marker of
apoptosis, sFas, suggests that hypoxia activation of apopto-
sis may be the main source of plasmatic nucleic acids in
PE. Further studies should analyze the relevance of plasma
mt-DNA and H-FBAP in rapidly identifying patients with
massive PE embolism at the highest risk of mortality who
may benefit from catheter-directed therapies if they are
unable to receive thrombolytics.
Key messages
• Plasma mt-DNA and n-DNA concentrations are sen-
sitive global indicator of 15-day mortality in patients
arriving at the emergency department with massive PE.
• Plasma mitochondrial DNA concentration in the
emergency department was 2 times higher in hospi-
tal nonsurvivors than in surviving patients.
• Plasma mt-DNA concentration is more powerful
predictor than H-FBAP or n-DNA on admission.
• Both plasma mt-DNA and H-FABP concentrations
are strong independent early predictors for hospital
mortality, whereas the plasma nuclear DNA seems
to have a lower relevance.
• The observed significant association of circulating
apoptosis markers sFas with plasma mitochondrial
DNA could reflect the anoxia activation of the mito-
chondrial pathway of apoptosis.
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